Andrew Witty, chief executive of the drug maker GlaxoSmithKline, said on Wednesday that the accusations of bribery and corruption against his company in China were “deeply disappointing.” But he said that Glaxo’s headquarters in London had not been aware of any fraud and that the executives under scrutiny in China were working “outside of our system of controls.”